Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.
about
Combined oral contraceptives: venous thrombosisAssessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysisReview of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pillEffects of oral contraceptives on selected parameters of the homeostatic control system in young women having a sudden disorder of the auditory and/or balance system.Endothelial function, endothelin-1, and fibrinogen in young women using the vaginal contraceptive ring.Ethinyl estradiol-to-desogestrel ratio impacts endothelial function in young womenOral contraception and risk of a cerebral thromboembolic attack: results of a case-control study.Estimating systemic exposure to ethinyl estradiol from an oral contraceptive.Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism.Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study.A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptivesComparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study.Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study.Clotting factor changes during the first cycle of oral contraceptive use.Venous thromboembolism in women.The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study.Contraceptive options during perimenopause.Lacunar infarction with oral contraceptives: An unusual case report.Risk of venous thromboembolism with drospirenone in combined oral contraceptive products.Risk factors for heart attack, stroke, and venous thrombosis associated with hormonal contraceptive use.Safety of medical treatments for endometriosis.Oral steroid contraception.Oral Contraceptives and HRT Risk of Thrombosis.A survey of bonobo (Pan paniscus) oral contraceptive pill use in North American zoos.Endogenous thrombin potential changes during the first cycle of oral contraceptive use.A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.Rotation thromboelastography (ROTEM) parameters are influenced by age, gender, and oral contraception.Risks of thromboembolism associated with hormone contraceptives in Japanese compared with Western women.Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study.Association between progestin-only contraceptive use and cardiometabolic outcomes: A systematic review and meta-analysis
P2860
Q24198113-26A7B533-CCFD-4DE7-8F8C-A4B3D7624297Q24622035-49FC27A9-1C91-4132-9D70-914B2184E2A7Q28300697-A7D14880-EBDD-4A54-BE12-8FDB6D3E0396Q30420494-53EAE452-6194-4098-B0A9-04C1016BD444Q34447839-EE62E8E9-B830-4900-A5D9-A99E095C6EB2Q34447854-2BEA858A-8F60-4698-A989-5176C97133CBQ35187685-27D8ACF0-0730-4425-AF85-A29588527817Q35561722-9C53E007-E1CA-441A-8880-8BCA4BF03810Q35599726-9EB1F819-D8A7-4E0D-90FA-C18DD63E95FEQ35664040-C95FE39D-81B4-4FD6-8AEB-CE2EB3CEC037Q36055436-5F330D70-3D53-44B9-BA23-FAC847593FF5Q36153437-B48B052F-B1BA-4571-85EB-C16D6B0C7308Q36887503-D3529C92-3BD2-4EAE-AF18-69204F970FF5Q37216764-1DDF04EB-0870-4EE9-AB95-8D3F96560E3DQ37238147-CE817A9A-6D82-486A-BE80-2C4456166594Q37305295-6F891B78-BD21-47CA-9E24-2238C3F49AC3Q37608428-4DD1D82D-B147-499C-AE86-28E12B43C4D9Q37634801-309358E5-5EEE-4058-A16A-2C2F5069062AQ37725569-F8AFDAD1-98B3-4CD7-8D0B-0EC2AC36D923Q37763371-4B0C235C-5CCC-4A31-99EA-A9090CF16E0CQ38635759-6D2C3DF2-EA3C-44E6-A932-5400C5816249Q38670998-A34F5538-F3ED-45DB-AFC1-73215E639053Q39066094-87FC1961-A87B-4B24-BA16-FE690D3006D2Q39550818-E8FD339B-8562-4688-8DC6-152F6A180A9BQ40380754-AF66901A-5C33-487D-8135-0E35E634E3D5Q51101026-F3FFDCAC-9422-4D95-9E94-6AC693EE615CQ51464446-144958C3-8781-4F82-A47F-7472B26D559EQ51827826-581BA07D-D8CE-4551-80E1-D1D3FF773791Q55331272-CF7B9FAE-EFD1-4E94-8EF1-B8576E718320Q57418618-80647C98-3228-407D-B478-C119E334BB16
P2860
Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.
@en
type
label
Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.
@en
prefLabel
Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.
@en
P2093
P1476
Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.
@en
P2093
P356
10.1093/OXFORDJOURNALS.AJE.A115799
P407
P577
1991-01-01T00:00:00Z